ASSEMBLY BIOSCIENCES, INC. - 8-K Filing
Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV), into primary biliary cholangitis and primary sclerosing cholangitis. The Phase 1a trial in healthy participants has been completed, with a planned Phase 2 study in HDV expected to begin Q4 2026 and a basket study focused on PBC/PSC anticipated for Q1 2027. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ASMB